Metastatic Hormone-sensitive Prostate Cancer
Showing 1 - 25 of >10,000
Metastatic Hormone-Sensitive Prostate Cancer Trial (Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment)
Not yet recruiting
- Metastatic Hormone-Sensitive Prostate Cancer
- Rezvilutamide
- +2 more
- (no location specified)
Nov 10, 2023
Learn More About How Safe Darolutamide is Under Real-world
Not yet recruiting
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- No Intervention
-
Multiple Locations, JapanMany Locations
Aug 24, 2023
Apalutamide in Metastatic Hormone Sensitive Prostate Cancer
Not yet recruiting
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
-
Cardiff, United Kingdom
- +4 more
Aug 25, 2023
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Trial (dalpiciclib isethionate tablets; abiraterone acetate
Not yet recruiting
- High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
- dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- placebo; abiraterone acetate tablets; prednisone tablets
- (no location specified)
Oct 20, 2023
Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer Trial in Umeå (Moderate hypo-fractionation,
Recruiting
- Prostate Cancer
- +2 more
- Moderate hypo-fractionation
- Ultra-hypo-fractionation
-
Umeå, SwedenCancercenter University hospital of Umeå
Nov 1, 2022
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)
Recruiting
- Metastatic Prostate Cancer
- +2 more
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023
Metastatic Hormone-Sensitive Prostate Cancer Trial in Saint Louis (biological, drug, device, procedure)
Completed
- Metastatic Hormone-Sensitive Prostate Cancer
- PROSTVAC-V
- +9 more
-
Saint Louis, MissouriWashington University School of Medicine
Aug 3, 2022
Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)
Not yet recruiting
- Prostate Cancer
- Docetaxel
- +2 more
-
Chicago, IllinoisNorthwestern University
Sep 27, 2023
Oligometastatic Hormone Sensitive Prostate Cancer Trial in Florence (SBRT on all sites of metastatic disease+Apalutamide)
Not yet recruiting
- Oligometastatic Hormone Sensitive Prostate Cancer
- SBRT on all sites of metastatic disease+Apalutamide
-
Florence, ItalyAOU Careggi Radiation Oncology Unit
Jan 29, 2023
Metastatic Hormone Refractory Prostate Cancer Trial in Saint Louis (Cabozantinib, Nivolumab, Abiraterone acetate)
Recruiting
- Metastatic Hormone Refractory Prostate Cancer
- Cabozantinib
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Jun 6, 2022
Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,
Recruiting
- Hormone Sensitive Metastatic Prostate Cancer
- +3 more
- Docetaxel
- +2 more
-
Nanjing, Jiangsu, ChinaDepartment of Urology, Drum Tower Hospital, Medical School of Na
Jul 13, 2022
Based Discrete Choice Experiment Study in Prostate Cancer Study
Completed
- Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer
-
Durham, North CarolinaDuke Clinical Research Institute
Jan 10, 2023
Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)
Recruiting
- Metastatic Hormone-sensitive Prostate Cancer
- Darolutamide (BAY1841788, Nubeqa)
- ADT
-
Homewood, Alabama
- +11 more
Jan 13, 2023
Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)
Active, not recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 12, 2023
Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography Trial in Umeå, Jönköping (stereotactic body
Recruiting
- Prostate Cancer Metastatic
- +2 more
- stereotactic body radiotherapy
- +2 more
-
Umeå, Umea, Sweden
- +1 more
May 19, 2022
Prostate Cancer Metastatic Trial in New York (REGN2810, Degarelix, Leuprolide Acetate)
Recruiting
- Prostate Cancer Metastatic
- REGN2810
- +3 more
-
New York, New YorkColumbia University Irving Medical Center
Mar 22, 2022
Metastatic Hormone Sensitive Prostate Cancer Trial in China (Enzalutamide, Placebo, Androgen deprivation therapy (ADT))
Active, not recruiting
- Metastatic Hormone Sensitive Prostate Cancer
- Enzalutamide
- +2 more
-
Beijing, China
- +29 more
Jan 7, 2023
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of
Recruiting
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- 6-month course of antiandrogen drugs
- Long-term course of antiandrogen drugs
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023
Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer Trial in Shanghai (drug, procedure, radiation)
Not yet recruiting
- Metastatic Prostate Cancer
- Castration-Sensitive Prostate Cancer
- apalutamide
- +3 more
-
Shanghai, Shanghai, China
- +1 more
Feb 4, 2023
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial (Pharmacotherapy
Not yet recruiting
- Castration-Sensitive Prostate Carcinoma
- +4 more
- Pharmacotherapy Discontinuation
- +3 more
- (no location specified)
Feb 11, 2022
Metastatic Hormone Sensitive Prostate Cancer Treated With
Not yet recruiting
- Metastatic Hormone-sensitive Prostate Cancer
-
Innsbruck, Austria
- +42 more
Jun 5, 2023
Prostate Cancer Metastatic Trial in New York (Actinium-J591, Stereotactic Body Radiation Therapy, Androgen Deprivation Therapy)
Not yet recruiting
- Prostate Cancer Metastatic
- Actinium-J591
- +2 more
-
New York, New YorkWeill Cornell Medicine - New York Presbyterian Hospital
Oct 3, 2022
Prostate Cancer Trial in Shatin (Apalutamide, Enzalutamide)
Recruiting
- Prostate Cancer
-
Shatin, Hong KongPrince of Wales Hospital
Aug 3, 2021